AOD-9604 and Tirzepatide Stack: Metabolic Synergy Amid FDA Scrutiny
AOD-9604 and tirzepatide are being studied for their potential metabolic synergy in targeting stubborn fat. This article examines the research, regulatory
Research Blog
Semaglutide vs. Retatrutide: FDA Panel’s Triple-Agonist Shift
The FDA peptide panel is evaluating retatrutide, a triple-agonist, against semaglutide for weight loss. Research shows retatrutide may achieve greater